###### Strengths and limitations of this study

-   This is the first multicentre multinational study in the Middle East to provide a report on the prevalence, demographics, management and 1-year outcome of patients hospitalised with HF in relation to a history of stroke that included a relatively large number of patients.

-   As an observational study, the possibility for unmeasured confounding biases exists. The current study has not recorded the cognitive status and the disability status in patients with stroke, which have a major impact on morbidity.

-   Furthermore, no information is available regarding the cause of stroke (embolic vs thrombotic), and future studies need to overcome these limitations.

-   Mortality rates at follow-up were only recorded at 1 year without the specification of the exact date of death of each patient.

Introduction {#s1}
============

The prevalence and incidence of stroke in patients with heart failure (HF) and the temporal relation of these two diseases in terms of increasing morbidity and mortality have scarcely been reported from around the world and never from the Middle East. HF is one of the leading causes of hospitalisation, and is a significant factor for morbidity and mortality worldwide. Moreover, HF is a major risk factor for the development of ischaemic stroke with a 2--3-fold increased risk of stroke when compared with patients without HF.[@R1] Factors that may contribute to the occurrence of stroke in HF include: atrial fibrillation (AF) or left ventricular (LV) dysfunction that are potential source embolisation.[@R2] [@R3] The hypercoagulable state and reduced fibrinolysis are a consequence of the activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system.[@R4] [@R5] In addition to endothelial dysfunction in HF,[@R6] [@R7] hypotension may also be an additional risk factor for stroke as a result of HF.[@R8] Moreover, underlying risk factors for the development of HF, such as hypertension and diabetes mellitus,[@R9] can also predispose to large-artery atherosclerosis and small-vessel thrombosis and hence stroke.[@R10]

The prevalence and incidence of prior and acute stroke in patients with HF is unclear because of the heterogeneous nature of the limited published studies, most of which were subset analyses of randomised trials rather than epidemiological studies.[@R11] Furthermore, most of the available data are mainly limited to studies conducted in the western world and data about the prevalence of prior stroke among patients hospitalised with HF are lacking. The aim of this study is to define the prevalence, clinical characteristics, precipitating factors, management and outcome of patients with stroke hospitalised with HF, using data from Gulf CARE (Gulf aCute heArt failuRe rEgistry).[@R18] It is hypothesised that patients with prior stroke when hospitalised with HF have worse outcomes when compared with patients with HF and without prior stroke.

Patients and methods {#s2}
====================

Registry design {#s2a}
---------------

Gulf CARE is a prospective multinational multicentre registry that recruited patients from February 2012 to November 2012 who were admitted with the final diagnosis of acute HF (AHF) in 47 hospitals in seven Middle Eastern Arab countries in the Gulf.[@R18] Data were collected on episodes of hospitalisation beginning with point of initial care, with patient\'s discharge, transfer out of hospital or in-hospital death, and for those discharged alive 3 and 12 months follow-up was obtained. Patients' recruitment was preceded by a pilot phase of 1 month in November 2011. Institutional or national ethical committee or review board approval was obtained in each of the seven participating countries, and all patients provided informed consent. Each patient was given a unique identification number to prevent double counting. The study is registered at clinicaltrials.gov with the number NCT01467973.

Patients included in this registry were men and women aged 18 years and over with AHF who were admitted to participating hospitals. AHF was defined based on the European Society of Cardiology (ESC) definition[@R2] and was further classified as either acute decompensated chronic HF (ADCHF) or new-onset AHF (de novo AHF) based on the ESC guidelines. ADCHF was defined as worsening of HF in patients with a previous diagnosis or hospitalisation for HF. New-onset AHF (de novo AHF) was defined as AHF in patients with no history of HF.

Patients were excluded from Gulf CARE if: (1) they were discharged from the emergency room without admission. (2) They were transferred from a non-registry hospital. (3) There was a failure to obtain informed consent. (4) Their final diagnosis was not HF, in which case they were also excluded from the final analyses. Registry organisation and Data Collection and Validation are mentioned in Gulf CARE.[@R18]

Definitions of data variables in the chronic renal failure (CRF) are based on the ESC guidelines 2008 and the American College of Cardiology clinical data standards 2005.[@R19] [@R20] Cardiomyopathy was defined as a myocardial disorder in which the heart muscle is structurally and functionally abnormal (in the absence of coronary artery disease, hypertension, valvular disease or congenital heart disease) sufficient to cause the observed myocardial abnormality.[@R20] Diastolic HF was defined as the presence of symptoms and/or signs of HF and a preserved LV ejection fraction (LVEF) \>40%.[@R19] Stroke/transient ischaemic attack (TIA) was defined as a history of cerebrovascular disease, documented by any one of the following: (1) cerebrovascular ischaemic or haemorrhagic stroke: patient has a history of stroke (ie, any focal neurological deﬁcit of abrupt onset caused by a disturbance in blood supply that did not resolve within 24 h) conﬁrmed by a standard neurological examination with or without a positive imaging study, or an event of presumed ischaemic origin that did not resolve within 24 h, but the imaging showed a new lesion. (2) TIA: patient has a history of any sudden new focal neurological deﬁcit of presumed ischaemic origin as determined by a standard neurological examination that resolved completely within 24 h, with a brain image study not revealing a new lesion. (3) Non-invasive/invasive carotid test with occlusion greater than or equal to 75%. (4) Previous carotid artery surgery. (5) Previous carotid angioplasty.[@R19] Diabetes mellitus was defined as having a history of diabetes diagnosed and treated with medication and/or insulin or fasting blood glucose 7.0 mmol/L (126 mg/dL) or glycated haemoglobin (HbA1c) ≥6.5%. Hypertension was defined as having a history of hypertension diagnosed and treated with medication, blood pressure greater than 140 mm Hg systolic or 90 mm Hg diastolic on at least two occasions or greater than 130 mm Hg systolic or 80 mm Hg diastolic on at least two occasions for patients with diabetes or chronic kidney disease (CKD). Hyperlipidaemia was defined as a history of dyslipidemia diagnosed and/or treated by a physician or total cholesterol greater than 5.18 mmol/L (200 mg/dL), low-density lipoprotein greater than or equal to 3.37 mmol/L (130 mg/dL) or high-density lipoprotein less than 1.04 mmol/L (40 mg/dL). Current smoker was defined as a person smoking cigarettes, a water pipe, a cigar or chewing tobacco within 1 month of index admission.

CKD was defined as glomerular filtration rate (GFR) \<60 mL/min/ 1.73 m^2^ for 3 months or more, with or without kidney damage or on dialysis. If no GFR was available, serum creatinine \>177 mmol/L or 2 mg/dL was marked as CKD. Obesity was defined as body mass index greater than 25 kg/m^2^. In the registry, infection is defined as any systemic infection needing antibiotics.[@R20]

Statistical analysis {#s2b}
--------------------

Baseline and outcome data are presented in frequency and percentages for categorical variables and interval variables are presented in mean and SDs or median and range as appropriate. In order to establish the association between stroke and non-stroke groups χ^2^ tests were applied. Student t tests or Wilcoxon rank sum tests were used for interval variables between the two groups as appropriate. Multivariate logistic regression analysis was performed at in-hospital and 1 year mortality for important risk factors. Adjusted OR and 95% CI with p values are presented in [table 6](#BMJOPEN2014007148TB6){ref-type="table"}. p Value ≤0.05 (two tailed) is considered statistically significant. SPSS V.21.0 Statistical package was used for the analysis.[@R21]

Results {#s3}
=======

Patient demographics {#s3a}
--------------------

Approximately 8.1% of Gulf CARE patients (total 5005 patients) had a history of stroke, with no significant gender or racial differences between stroke and non-stroke groups ([tables 1](#BMJOPEN2014007148TB1){ref-type="table"}[](#BMJOPEN2014007148TB2){ref-type="table"}--[3](#BMJOPEN2014007148TB3){ref-type="table"}). Patients with stroke with HF were older (66.5 vs 59 years, p=0.001) and more likely to have diabetes mellitus, hypertension, AF, coronary artery disease and LV dysfunction (p=0.001). Patients with stroke were also more likely to have chronic kidney disease and to be on renal replacement therapy than patients without stroke (p=0.001) and to have thyroid disease (6.2% vs 3.4%, p=0.001) and previous coronary artery bypass grafting (7% vs 10.9%, p=0.004) and less likely to be smokers (p=0.003) or have a history of asthma/chronic obstructive pulmonary disease. Patients with stroke were more likely to present with ADCHF with more frequent recent (≤6 months) HF hospitalisations (p=0.001), and more likely to be admitted under the care of internists rather than cardiologists when compared with patients without stroke.

###### 

Baseline demographic and clinical characteristics (no stroke/TIA vs stroke/TIA)

  ----------------------------------------------------------------------------------------------
  Variable                                             No stroke/TIA\   Stroke/TIA\    p Value
                                                       N=4601 (91.9%)   N=404 (8.1%)   
  ---------------------------------------------------- ---------------- -------------- ---------
  Acute new-onset heart failure (%)                    2150 (46.7)      126 (31.2)     

  Acute decompensated chronic heart failure (%)        2451 (53.3)      278 (68.8)     0.001

  Age (mean ±SD)                                       59±14.9          66.5±13        0.001

  Gender                                                                               

   Male (%)                                            2892 (62.9)      239 (59.2)     

   Female (%)                                          1709 (31.1)      165 (40.8)     0.14

  Ethnicity                                                                            

   Arab (%)                                            4130 (89.8)      386 (95.5)     

   Asians (%)                                          455 (9.9)        18 (4.5)       

   Others (%)                                          16 (0.3)         0 (0)          0.001

  Main caregiver                                                                       

   Cardiologist (%)                                    3326 (72.3)      249 (61.6)     

   Internist (%)                                       1275 (27.7)      155 (38.4)     0.001

  *Previous CV history*                                                                

  HF previous admission (%)                                                            

   ≤6 months (%)                                       2439 (53)        278 (68.8)     0.001

  Known systolic LV dysfunction (%)                    2053 (44.6)      228 (56.4)     0.001

  Known CAD (%)                                        2083 (45.3)      254 (62.9)     0.001

  Valvular heart disease (%)                           608 (13.2)       67 (16.6)      0.06

  PVD (%)                                              162 (3.5)        61 (15.1)      0.001

  Atrial fibrillation (%)                              569 (11.1)       98 (24.3)      0.001

  Current smoking (%)                                  1038 (22.6)      65 (16.1)      0.003

  Type 1 DM (%)                                        160 (3.5)        25 (6.2)       

  Type 2 DM (%)                                        2052 (44.6)      255 (63.1)     0.001

  Known HTN (%)                                        2718 (59.1)      341 (84.4)     0.001

  Known hyperlipidaemia (%)                            1572 (34.2)      227 (56.2)     0.001

  CKD/dialysis (%)                                     631 (13.7)       113 (28)       0.001

  Sleep apnoea requiring therapy (%)                   88 (1.9)         11 (2.7)       0.26

  Family history of cardiomyopathy/heart failure (%)   244 (5.3)        15 (3.7)       0.17

  Khat (%)                                             852 (18.5)       39 (9.7)       0.001

  Alcohol (%)                                          165 (3.6)        11 (2.7)       0.63

  Peripartum (at present) (%)                          76 (1.7)         2 (0.5)        0.07

  Radiation (%)                                        19 (0.4)         0 (0)          0.20

  Chemotherapy (%)                                     29 (0.6)         3 (0.7)        0.79

  Thyroid disease (%)                                  156 (3.4)        25 (6.2)       0.001

  Asthma/COPD (%)                                      446 (9.7)        55 (13.6)      0.01
  ----------------------------------------------------------------------------------------------

CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; DM, diabetes mellitus; HTN, hypertension; LV, left ventricular; PVD, peripheral vascular disease; TIA, transient ischaemic attack.

###### 

Clinical presentation (symptoms, signs; stroke/TIA vs no stroke/TIA)

  -------------------------------------------------------------------------------
  Variable                              No stroke/TIA\   Stroke/TIA,\   p Value
                                        N=4601 (91.9%)   N=404 (8.1%)   
  ------------------------------------- ---------------- -------------- ---------
  Clinical symptoms                                                     

   Cardiac arrest (%)                   138 (3)          19 (4.7)       0.06

   NYHA I (%)                           124 (2.7)        5 (1.2)        

   NYHA II (%)                          933 (20.3)       72 (17.8)      

   NYHA III (%)                         1973 (42.9)      188 (46.5)     

   NYHA IV (%)                          1471 (32)        132 (32.7)     0.22

   Orthopnoea (%)                       3618 (78.6)      324 (80.2)     0.46

   Paroxysmal nocturnal dyspnoea (%)    2942 (63.9)      274 (67.8)     0.12

   Abdominal/lower limb swelling (%)    2055 (44.7)      187 (46.3)     0.53

   Weight gain (yes) (%)                1207 (26.2)      100 (24.8)     0.52

   Chest pain (%)                       2034 (44.2)      166 (41.1)     0.23

   Palpitation (%)                      1413 (30.7)      107 (26.5)     0.08

   Easy fatigability (%)                2604 (56.6)      230 (56.9)     0.89

   Syncope in the last 1 year (%)       218 (4.7)        45 (11.1)      0.001

  Clinical signs                                                        

   Heart rate (mean±SD)                 97±23            95±22.9        0

   BP (mm Hg) (mean±SD)                                                 

    Systolic                            137±34           142±33         0.01

    Diastolic                           81±20            80±19.5        0.37

   RR (mean±SD)                         24.6±5.9         24.9±5.8       0.32

   Weight (kg) (mean±SD)                74±17            76±17.6        0.02

   Height (cm) (mean±SD)                162±8.6          163±9          0.56

   Waist circumference (cm) (mean±SD)   92±15            93±16.7        0.84

   BMI (kg/m^2^) (mean±SD)              28±6             29±6.3         0.03

   Raised JVP\>6 cm (%)                 2323 (56.5)      203 (50.2)     0.93

   Peripheral oedema (%)                2496 (54.2)      231 (57.2)     0.26

   Ascites (%)                          658 (14.3)       65 (16.1)      0.33

   Enlarged tender liver (%)            1260 (27.4)      78 (19.3)      0.001

   Gallop (%)                           1747 (38)        129 (31.9)     0.02

   Basal lung crepitation (%)           4214 (91.6)      383 (94.8)     0.02

   Signs of pleural effusion (%)        847 (18.4)       77 (19.1)      0.75
  -------------------------------------------------------------------------------

BMI, body mass index; BP, blood pressure; JVP, jugular venous pressure; NYHA, New York Heart Association; RR, respiratory rate; TIA, transient ischaemic attack.

###### 

Medications and interventions (stroke/TIA vs no stroke/TIA)

  Variable                             Before admission   On discharge                                      
  ------------------------------------ ------------------ -------------- ------- ------------- ------------ -------
  Digoxin                              758 (16.5)         92 (22.8)      0.001   1112 (24.2)   95 (23.5)    0.77
  Oral nitrates                        1151 (25)          154 (38.1)     0.001   1636 (35.6)   186 (46)     0.001
  Hydralazine                          187 (4.1)          34 (8.4)       0.001   299 (6.5)     54 (13.4     0.001
  Aspirin                              2781 (60.4)        308 (76.2)     0.001   3538 (76.9)   313 (77.5)   0.80
  Clopidogrel                          849 (18.5)         117 (29)       0.001   1631 (35.5)   167 (41.3)   0.02
  Oral anticoagulants (%)              537 (11.7)         81 (20)        0.001   806 (17.5)    91 (22.5)    0.01
  Statin                               2269 (49.3)        286 (70.8)     0.001   311 (67.7)    319 (79)     0.001
  Allopurinol                          121 (2.6)          14 (3.5)       0.32    219 (4.8)     20 (5)       0.86
  Ivabradine (%)                       107 (2.3)          8 (2.0)        0.66    227 (4.9)     17 (4.2)     0.52
  Antiarrhythmic (%)                   116 (2.5)          10 (2.5)       0.96    208 (4.5)     15 (3.7)     0.45
  Antidepressants (%)                  57 (1.2)           9 (2.2)        0.10    82 (1.8)      10 (2.5)     0.32
  BB                                                                                                        
   Carvedilol                          992 (49.6)         105 (50.2)     0.87    1600 (51.6)   140 (53.8)   0.48
   Metoprolol                          197 (9.9)          26 (12.4)      0.24    295 (9.5)     32 (12.3)    0.14
   Bisoprolol                          648 (32.4)         59 (28.2)      0.22    1151 (37.1)   80 (30.8)    0.04
  ACE inhibitors                       1968 (42.8)        164 (40.6)     0.40    2694 (58.6)   188 (46.5)   0.001
  ARBs                                 563 (12.2)         84 (20.8)      0.001   725 (15.8)    77 (19.1)    0.08
  Aldosterone antagonists              778 (16.9)         62 (15.3)      0.42    1921 (41.8)   135 (33.4)   0.001
  Cardiac procedures                                                                                        
   PCI                                 484 (10.5)         55 (13.6)      0.05    2861 (6.2)    13 (3.2)     0.02
   CABG                                322 (7)            44 (10.9)      0.004   65 (1.4)      4 (1.0)      0.49
  Device therapy (yes) (%)                                                                                  
   CRT-P                               4 (0.1)            1 (0.2)                2 (0)         0 (0)        
   CRT-D                               52 (1.1)           4 (1.0)                26 (0.6)      3 (0.7)      
   ICD                                 80 (1.7)           12 (3)         0.37    45 (1.0)      8 (2.0)      0.10
  Valve repair/replacement (yes) (%)   148 (3.2)          19 (4.7)       0.11    88 (1.9)      6 (1.5)      0.54

ARBs, angiotensin receptors blockers; BB, B blockers; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; ICD, International Classification of Diseases; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.

Investigations during hospitalisation {#s3b}
-------------------------------------

Patients with stroke were more likely to be admitted with AF when compared with patients without stroke; atrial fibrillation/flutter (12.7% vs 24.9%, p=0.001; [table 4](#BMJOPEN2014007148TB4){ref-type="table"}). Patients with stroke were also more likely to have concentric LV hypertrophy (26.8% vs 32.7%, p=0.02), and less likely to have mitral regurgitation (30.4% vs 22.5%, p=0.001) with no differences in the mean EF on echocardiographic assessment between the two groups.

###### 

Investigations during hospitalisation (stroke/TIA vs no stroke/TIA)

  ----------------------------------------------------------------------------------
  Variable                                 No stroke/TIA\   Stroke/TIA\    p Value
                                           N=4601 (91.9%)   N=404 (8.1%)   
  ---------------------------------------- ---------------- -------------- ---------
  Pulse oximetry saturation (mean±SD)      93±6.9           93±6.2         0.86

  Troponin, ng/mL                                                          

   Elevated (%)                            1726 (37.5)      176 (43.6)     

   Normal (%)                              2453 (53.3)      198 (49)       

   Not performed (%)                       422 (9.2)        30 (7.4)       0.05

  First BNP or NT-Pro BNP, pg/mL           780 (17)         70 (17.3)      0.85

  HbA1c (mean±SD) (%)                      7.2±2.2          7.6±2.0        0.03

  Total cholesterol (mean±SD) mmol/L       4.8±2.3          4.5±2.2        0.02

  First haemoglobin (mean±SD) g/dL         12.7±2.4         11.9±2.3       0.001

  First WCC (mean±SD) cells/mL             10.4±8           10±7           0.89

  First urea (mean±SD) mmol/L              11±8.4           12.8±9         0.002

  First creatinine (mean±SD) mmol/L        129±117          146±111        0.003

  E-GFR (mean±SD) mL/min                   69±35.7          58±36.6        0.001

  First serum potassium (mean±SD) mmol/L   4.3±0.7          4.3±0.69       0.06

  First ALT (mean±SD) mmol/L               94±218           71±192         0.02

  ECG rhythm                                                               

   Sinus (%)                               3803 (83.2)      288 (71.8)     0.01

   AF/flutter (%)                          579 (12.7)       100 (24.9)     0.001

   Paced (%)                               69 (1.5)         10 (2.5)       0.13

   Others (%)                              62 (1.4)         1 (0.2)        0.05

   LVH (%)                                 1377 (29.9)      144 (35.6)     0.02

   STEMI (%)                               495 (10.8)       31 (7.7)       0.05

   AF                                      509 (11.1)       98 (24.3)      0.001

   CHB                                     56 (1.2)         2 (0.5)        0.20

   Pathological Q waves (old MI)           1072 (23.3)      106 (16.2)     0.18

   QRS duration ≥0.12 ms                   --                              

   LBBB                                    596 (13)         61 (15.1)      0.22

   RBBB                                    203 (4.4)        19 (4.7)       0.79

   IVCD                                    142 (3.1)        17 (4.2)       0.22

  Echocardiography (available) (%)         4207 (91.4)      370 (91.6)     0.92

  Left atrial enlargement (yes) (%)        2658 (63.2)      239 (64.6)     0.59

  LVEF (mean±SD)                           37±14            36.5±13        0.57

  EF≤35%                                   1847 (43.9)      165 (44.6)     0.80

  EF\>35%                                  2360 (56.1)      205 (55.4)     0.80

  Concentric LVH                           1129 (26.8)      121 (32.7)     0.02

  Moderate-to-severe valve disease                                         

   MS                                      127 (2.8)        8 (2)          0.35

   MR                                      1400 (30.4)      91 (22.5)      0.001

   AS                                      115 (2.5)        8 (2.0)        0.52

   AR                                      177 (3.8)        12 (3.0)       0.38

   TR                                      646 (14)         49 (12.1)      0.29

  PA systolic pressure (mean±SD)           55.7±16          53±11          0.03

  Coronary angiogram (within 1 year) (%)   1017 (22.1)      74 (18.3)      0.08

  SVD                                      183 (4)          10 (2.5)       0.13

  DVD                                      204 (4.4)        10 (2.5)       0.06

  TVD                                      313 (6.8)        30 (7.4)       0.64

  LMSD                                     16 (0.3)         0 (0)          0.24

  Blocked stent/graft                      23 (0.5)         6 (1.5)        0.01
  ----------------------------------------------------------------------------------

AF, atrial fibrillation; ALT, alanine transaminase; AR, aortic regurgitation; AS, aortic stenosis; BNP, brain natriuretic peptide; CHB, complete heart block; DVD, double vessel disease; EF, ejection fraction; GFR, glomerular filtration rate; HbA1c, glycated haemoglobin; IVCD, intra-ventricular conduction delay; LBBB, left bundle branch block; LMSD, left main disease; LVH, left ventricular hypertrophy; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MR, mitral regurgitation; MS, mitral stenosis; NT-Pro BNP, N-terminal Pro brain natriuretic peptide; PA, pulmonary artery; RBBB, right bundle branch block; STEMI, ST elevation myocardial infarction; SVD, single vessel disease; TIA, transient ischaemic attack; TR, tricuspid regurgitation; TVD, tripe vessel disease, WCC, white cell count.

Patients with stroke were more likely to have a lower GFR (mean±SD; 58±36.6 vs 69±35.7, p=0.001 and, as a result, higher serum creatinine (mean±SD; 146±111 vs129±117 mg/dL, p=0.003) and blood urea (mean±SD: 12.8±9 vs 11±8.4 mg/dL, p=0.002). Patients with stroke were also more likely to have lower admission haemoglobin levels (mean±SD; 11.9±2.3 vs 12.7±2.4 mg/dL, p=0.001).

Precipitating factors, hospitalisation course and outcomes {#s3c}
----------------------------------------------------------

There were no significant differences in terms of precipitating factors for HF hospitalisation between the two groups ([tables 5](#BMJOPEN2014007148TB5){ref-type="table"} and [6](#BMJOPEN2014007148TB6){ref-type="table"}).

###### 

Course in the hospital and in-hospital and 1-year outcome (stroke/TIA vs no stroke/TIA)

  ----------------------------------------------------------------------------------------
  Variable                                       No stroke/TIA\   Stroke/TIA\    p Value
                                                 N=4601 (91.9%)   N=404 (8.1%)   
  ---------------------------------------------- ---------------- -------------- ---------
  Precipitating factors for HF                                                   

   Medications non-compliance (%)                878 (19.1)       86 (21.3)      0.28

   Non-compliance with diet (%)                  129 (2.8)        7 (1.7)        0.20

   Salt retaining drugs (%)                      26 (0.6)         0 (0)          0.13

   Acute coronary syndrome (%)                   1259 (27.4)      106 (26.2)     0.63

   Uncontrolled hypertension (%)                 374 (8.1)        36 (8.9)       0.58

   Uncontrolled arrhythmia (%)                   271 (5.9)        30 (7.4)       0.21

   Anaemia (%)                                   138 (3)          16 (4)         0.28

   Infection (%)                                 667 (14.5)       641 (15.8)     0.46

   Unknown (%)                                   651 (14.1)       35 (8.7)       0.002

   Worsening of renal failure                    197 (4.3)        24 (5.9)       0.12

  NIV                                            411 (8.9)        62 (15.3)      0.001

  Intubation/ventilation                         374 (8.1)        50 (12.4)      0.003

  Inotropes                                      695 (15.1)       88 (21.8)      0.001

  IABP                                           76 (1.7)         6 (1.5)        0.80

  Acute dialysis/ultrafiltration                 117 (2.5)        18 (4.5)       0.02

  VT/VF requiring therapy (%)                    202 (4. 4)       20 (5.0)       0.60

  AF requiring therapy (%)                       265 (5.8)        46 (11.4)      0.001

  Major bleeding (%)                             37 (0.8)         3 (0.7)        0.90

  Blood transfusion (%)                          217 (4.7)        37 (9.2)       0.001

  In-hospital new stroke (%)                     46 (1)           22 (5.4)       0.001

  Systemic infection requiring antibiotics (%)   1067 (23.2)      141 (34.9)     0.001

  HHD                                            725 (15.8)       77 (19.1)      0.08

  IHD                                            2424 (42.7)      239 (59.2)     0.01

  Primary VHD                                    432 (9.4)        29 (7.2)       0.14

  Viral myocarditis (%)                          17 (0.4)         0 (0.0)        0.22

  Cardiomyopathy (total)                         862 (18.7)       53 (13.1)      0.005

  CM subtype                                                                     

   HCM                                           19 (0.4)         3 (0.7)        0.34

   Infiltrative CM                               12 (0.3)         1 (0.2)        0.96

   Toxic CM                                      36 (0.8)         3 (0.7)        0.93

   Pregnancy-related CM                          63 (1.4)         2 (0.5)        0.14

   Thyroid disease-related CM                    10 (0.2)         0 (0)          0.35

   Familial CM                                   9 (0.2)          0 (0)          0.37

   Tachycardia-induced CM                        30 (0.7)         1 (0.2)        0.32

   Idiopathic DCM                                605 (13.1)       37 (9.2)       0.02

  Discharge home                                 4104 (89.2)      350 (86.6)     0.30

  Transfer to another hospital                   80 (1.7)         8 (2.0)        0.30

  Death                                          279 (6.1)        34 (8.4)       0.06

  Hospital stay (days) (mean±SD)                 9±13             11±14          0.03

  Alive (yes)                                    3532 (76.8)      272 (67.3)     0.001

  HF rehospitalisation (yes) (%)                 989 (28)         86 (31.6)      0.20

  Cardiac intervention needed                                                    

   ICD                                           33 (0.7)         1 (0.2)        0.27

   CRTD/P                                        12 (0.2)         2 (0.5)        0.33

   PCI/CABG                                      358 (10.1)       22 (8.1)       0.28
  ----------------------------------------------------------------------------------------

AF, atrial fibrillation; CABG, coronary artery bypass grafting; CRTD, cardiac resynchronisation therapy, defibrillator; CRT, Cardiac resynchronization therapy; CM, cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HHD, hypertensive heart disease; IABP, intra-aortic balloon pump insertion; ICD, International Classification of Diseases; IHD, ischaemic heart disease; NIV, non-invasive ventilation; PCI, percutaneous coronary intervention; VF, ventricular fibrillation; VHD, valvular heart disease; VT, ventricular tachycardia.

###### 

Multivariate logistic regression analysis for in-hospital mortality

  Variable                                                         Adjusted OR   95% CI         p Value
  ---------------------------------------------------------------- ------------- -------------- ---------
  Age                                                              0.99          0.98 to 1.03   0.16
  Male gender                                                      0.78          0.59 to 1.04   0.09
  DM II                                                            1.06          0.79 to 1.41   0.70
  CKD                                                              1.31          0.91 to 1.89   0.15
  COPD/asthma                                                      0.64          0.37 to 1.10   0.11
  STEMI                                                            2.25          1.57 to 3.23   0.001
  LVEF≥35%                                                         0.77          0.59 to 1.01   0.06
  LVEF\<35                                                         1.30          0.99 to 1.70   0.06
  VHD                                                              1.59          1.12 to 2.25   0.009
  Stroke                                                           1.71          1.13 to 2.60   0.01
  PVD                                                              1.52          0.89 to 2.62   0.13
  Multivariate logistic regression analysis for 1-year mortality                                
   Age                                                             1.04          1.03 to 1.05   0.001
   Male gender                                                     1.12          0.90 to 1.40   0.31
   DM II                                                           1.18          0.95 to 1.46   0.13
   CKD                                                             1.53          1.19 to 1.96   0.001
   COPD/asthma                                                     1.22          0.91 to 1.65   0.19
   STEMI                                                           0.89          0.62 to 1.29   0.55
   LVEF≥35                                                         0.74          0.60 to 0.91   0.005
   LVEF\<35                                                        1.35          1.10 to 1.67   0.005
   VHD                                                             1.46          1.10 to 1.93   0.009
   Stroke                                                          1.34          0.98 to 1.84   0.07
   PVD                                                             1.20          0.79 to 1.82   0.41
  Risk factors for stroke in heart failure                                                      
   Age                                                             1.02          1.01 to 1.03   0.001
   Gender                                                          1.02          0.81 to 1.28   0.88
   DM                                                              1.30          1.01 to 1.69   0.045
   HTN                                                             2.10          1.50 to 2.80   0.001
   Systolic BP                                                     1.0           0.99 to 1.01   0.51
   Diastolic BP                                                    1.0           0.99 to 1.01   0.65
   NYHA I                                                          0.64          0.19 to 2.14   0.33
   NYHA II                                                         0.98          0.42 to 2.25   0.46
   NYHA III                                                        1.24          0.55 to 2.80   0.95
   NYHA IV                                                         1.24          0.54 to 2.81   0.61
   Hyperlipidaemia                                                 1.30          1.02 to 1.65   0.03
   CKD                                                             1.31          1.05 to 1.75   0.045
   Systolic LV dysfunction                                         1.08          0.85 to 1.37   0.52
   Known CAD                                                       1.14          0.89 to 1.47   0.30
   PVD (%)                                                         2.97          2.06 to 4.12   0.001
   AF                                                              2.20          1.67 to 2.89   0.001
   Thyroid disease                                                 0.91          0.56 to 1.49   0.71

AF, atrial fibrillation; BP, blood pressure; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HTN, hypertension; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PVD, peripheral vascular disease; TIA, transient ischaemic attack; VHD, valvular heart disease.

Patients with stroke were more likely to require invasive and non-invasive ventilations (12.4% vs 8.1%, p=0.003), (15.3% vs 8.9%, p=0.001), respectively, and were also more likely to require inotropic support (21.8% vs 15.1%, p=0.001), AF therapy (11.4% vs 5.8%, p=0.001%), renal replacement therapy (2.5% vs 4.5%, p=0.02) and blood transfusions (9.2% vs 4.7%, p=0.001) when compared with patients without stroke. Patients with stroke were also more likely to suffer recurrent strokes and have systemic infections that require antibiotic treatment (34.9% vs 23.2%, p=0.001) during the same hospitalisation when compared with patients without stroke ([table 5](#BMJOPEN2014007148TB5){ref-type="table"}). The clinical workup of patients with stroke showed that they were more likely to have ischaemic heart disease (59.2% vs 42.7%, p=0.01) and less likely to have other types of cardiomyopathies (13.1% vs 18.7% p=0.005), including idiopathic cardiomyopathy (9.2% vs 13.1%, p=0.02; [table 5](#BMJOPEN2014007148TB5){ref-type="table"}).

Patients with stroke were more likely to be discharged on oral nitrates, hydralazine, statin, ACE inhibitors (ACEIs), aldosterone antagonists (p=0.001), oral anticoagulants (p=0.02) and clopidogrel (p=0.01) when compared with patients without stroke ([table 3](#BMJOPEN2014007148TB3){ref-type="table"}). In comparison with stroke patients non-stroke patients had percutaneous coronary intervention during hospitalisation (p=0.02).

Patients with stroke had a longer hospital stay (mean±SD days; 11±14 vs 9±13, p=0.03) as well as a higher but statistically non-significant in-hospital (8.4% vs 6.1%, p=0.06) and a significantly higher 1-year mortality rate (32.7% vs 23.2%, p=0.001; [table 5](#BMJOPEN2014007148TB5){ref-type="table"}). On multivariate logistic regression analysis, stroke was an independent mortality predictor for in-hospital and 1-year follow-up ([table 6](#BMJOPEN2014007148TB6){ref-type="table"}). Age, hypertension, peripheral vascular disease and AF were independent risk factors for stroke in patients with HF ([table 6](#BMJOPEN2014007148TB6){ref-type="table"}).

Cardiologist vs internist care {#s3d}
------------------------------

Subanalysis of patients with prior stroke according to whether the primary care provider is a cardiologist versus internist showed the following: patients admitted to cardiologists were more likely to be prescribed clopidogrel (48.2% vs 30.3%, p=0.001) and ACEI (51.8 vs 38.1%, p=0.007) and with less incidence of recurrent stroke (2% vs11%, p=0.001), less major bleeding (0% vs 1.9%, p=0.03) and the need for blood transfusion (6.4% vs 13.5%, p=0.02) when compared with patients with prior stroke hospitalised under the care of internists. Patients with prior stroke with systemic infection requiring antibiotics were more likely to be admitted under internal medicine care (46.5% vs 27.7%, p=0.001) with higher in-hospital mortality (13.5% vs 5.2%, p=0.009) with no significant differences in the duration of hospital stay (11±17 vs 10±10 (days), p=0.33) when compared with those admitted under cardiologist care. One year follow-up showed non-significant marginally higher rehospitalisation for patients under internist care (19.3% vs 24.5%, p=0.07) with significantly higher mortality when compared with patients under cardiologist care (69.9% vs 63.2%, p=0.002; [table 7](#BMJOPEN2014007148TB7){ref-type="table"}).

###### 

Patient with HF with stroke/TIA as per care provider

  Variable                                       Cardiologist care 249 (61.6%)   Internist care 155 (38.4%)   p Value
  ---------------------------------------------- ------------------------------- ---------------------------- ---------
  Acute new-onset HF (%)                         83 (33.3)                       43 (27.7)                    
  Acute decompensated chronic HF (%)             166 (66.7)                      112 (72.3)                   0.24
  Age (mean±SD)                                  66±13                           67±12                        0.36
  Male (%)                                       158 (63.5)                      81 (52.3)                    0.03
  Previous admission for HF (%)                  10 (4)                          5 (3.2)                      0.68
  AF                                             60 (24.1)                       38 (24.5)                    0.92
  CKD/dialysis (%)                               71 (28.5)                       42 (27.1)                    0.76
  PVD                                            44 (17.7)                       17 (11)                      0.07
  CAD                                            164 (65.9)                      90 (58.1)                    0.12
  NYHA III                                       106 (42.6)                      82 (52.9)                    0.04
  NYHA IV                                        83 (33.3)                       49 (31.6)                    0.72
  Clopidogrel                                    120 (48.2)                      47 (30.3)                    0.001
  Oral anticoagulants (%)                        60 (24.1)                       31 (20)                      0.34
  ACE inhibitors                                 129 (51.8)                      59 (38.1)                    0.007
  ARBs                                           43 (17.3)                       34 (21.9)                    0.25
  Aldosterone antagonists                        88 (35.3)                       47 (30.3)                    0.30
  LVEF (mean±SD)                                 35±12.6                         39±14                        0.01
  NIV                                            37 (14.9)                       25 (16.1)                    0.73
  Intubation/ventilation                         33 (13.3)                       17 (11)                      0.50
  Inotropes                                      48 (19.3)                       40 (25.8)                    0.12
  IABP                                           5 (2)                           1 (0.6)                      0.27
  Acute dialysis/ultrafiltration                 11 (4.4)                        7 (4.5)                      0.96
  VT/VF requiring therapy (%)                    14 (5.6)                        6 (3.9)                      0.43
  AF requiring therapy (%)                       27 (10.8)                       19 (12.3)                    0.66
  Major bleeding (%)                             0 (0)                           3 (1.9)                      0.03
  Blood transfusion (%)                          16 (6.4)                        21 (13.5)                    0.02
  In-hospital stroke (%)                         5 (2)                           17 (11)                      0.001
  Systemic infection requiring antibiotics (%)   69 (27.7)                       72 (46.5)                    0.001
  Death in-hospital                              13 (5.2)                        21 (13.5)                    0.009
  Hospital stay (days) (mean±SD)                 11±17                           10±10                        0.33
  1-year follow-up                                                                                            
   Alive (yes)                                   174 (69.9)                      98 (63.2)                    0.002
   HF hospitalisation (yes) (%)                  48 (19.3)                       38 (24.5)                    0.07
   ICD                                           0 (0)                           1 (0.6)                      0.20
   CRTD                                          2 (0.8)                         0 (0)                        0.26
   PCI/CABG                                      13 (7.5)                        9 (9.2)                      0.62

AF, atrial fibrillation; ARBs, angiotensin receptors blockers; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CKD, chronic kidney disease; CRTD, Cardiac resynchronization therapy, defibrillator; HF, heart failure; IABP, intra-aortic balloon pump insertion; ICD, International Classification of Diseases; LVEF, left ventricular ejection fraction; NIV, non-invasive ventilation; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; TIA, transient ischaemic attack, VF, ventricular fibrillation; VT, ventricular tachycardia.

Discussion {#s4}
==========

The current registry of patients hospitalised for HF demonstrates the following: (1) stroke history is relatively common among Middle Eastern patients. (2) Patients with stroke had a higher risk of recurrent in-hospital strokes and higher long-term mortality rates. (3) Prior stroke was an independent predictor of in-hospital and 1-year mortality. (4) Patients with stroke hospitalised with HF were more likely to be admitted under internist care rather than cardiologist care with less use of evidence-based medications.

HF is a common disease and is a major risk factor for ischaemic stroke. Stroke-related morbidity and mortality are considerably higher in patients with HF compared with patients with stroke without HF.[@R22] Data on the prevalence and outcome of stroke in patients hospitalised for HF are very sparse and mainly conducted in the western world. To the best of our knowledge, this is the first study from the Middle East and the developing world that explores this issue. We had previously reported a low prevalence of prior stroke in patients hospitalised with acute coronary syndrome (ACS) in the Middle East.[@R23] [@R24] On the other hand, this study reports a relatively higher prevalence of stroke in patients hospitalised with HF in seven Middle Eastern countries, suggesting that prior stroke is more prevalent among patients hospitalised with HF rather than ACS in this region.

Prevalence of stroke in patients with HF {#s4a}
----------------------------------------

The reported prevalence of stroke in patients with HF is variable because of the heterogeneous and limited number of published studies ([table 8](#BMJOPEN2014007148TB8){ref-type="table"}).[@R25] The initial risk of ischaemic stroke during the first year after diagnosis of HF was reported to be 1.8%; this compares with subsequent risk of nearly 5% at 5 years post-diagnosis.[@R25] Data from the Framingham Study[@R11] and a recent cohort study[@R12] indicated that the risk of ischaemic stroke is 2--3 times higher for patients with HF than it is for those without HF. According to epidemiological data, cohort studies and case series, ≈10% to 24% of all patients with stroke have HF, whereas HF is thought to be the likely cause of stroke in ≈9% of all patients.[@R13] A meta-analysis including 15 clinical studies and 11 cohort studies published before 2006[@R25] reported a stroke rate of 1.8% and 4.7% within 1 and 5 years, respectively. A recent report from the population-based, prospective Rotterdam Scan Study revealed that stroke risk is highest within 1 month after the diagnosis of HF that normalised within 6 months.[@R32]

###### 

Prevalence of stroke in patients with HF/studies from different parts of the world

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Study name (reference)           Study period                         Patient (n)   Mean age (years)   Female sex (%)   Strokes (%)   F/U\* (days)
  -------------------------------- ------------------------------------ ------------- ------------------ ---------------- ------------- --------------
  Granger *et al*[@R26]\           CHARM-Alternative trial 1999--2001   2028          66.5               31.9             3.8           1011
  North America Europe                                                                                                                  

  Mathew *et al*[@R27]\            DIG trial 1991--1993                 7788          63.9               24.7             4.2           1110
  North America                                                                                                                         

  Pfeffer *et al*[@R28]\           CHARM-Overall programme 1999--2001   7599          66                 31.6             1.4           1131
  North America Europe                                                                                                                  

  Dries *et al*[@R29]\             SOLVD trial 1986--1989               6378          60                 4.4              3.5           1197
  North America                                                                                                                         

  McMurray *et al*[@R30]\          CHARM-Added trial 1999               2548          64                 21.3             3.4           1230
  26 countries worldwide                                                                                                                

  Remme *et al*[@R31] Europe       COMET trial 1996--1999               3029          62                 0.2              4.7           1740

  Khafaji *et al* current study\   Gulf CARE\                           5005          66.5               40.8             8.1           360
  Middle East                      2012--2013                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------

\*Included studies in the follow-up period. Gulf CARE, Gulf aCute heArt failuRe rEgistry.

This study complements previous reports by showing high prevalence of prior stroke among patients hospitalised with HF in the Middle East. Moreover, patients with a prior stroke had a higher risk of recurrent strokes during the index hospitalisation. This high prevalence may be due to associated risk factors for stroke such as severe LV systolic dysfunction (44.6% had EF \<35%) and AF (25%), even though there was a relatively high prevalence of associated risk factors, including LV dysfunction and AF, while the use of anticoagulants and antiplatelet agents was low In this study, we reported the use of anticoagulants (20--22%) and antiplatelets (29--41%) during hospitalisation at discharge, respectively, in patients with prior stroke; this rate may be much lower than has been reported in a EUROASPIRE III survey where antiplatelet drugs or oral anticoagulants were used by 87.2%, of patients with stroke.[@R33] This lower use of anticoagulants and antiplatelets in this study may have contributed to their increased risk of recurrent strokes and higher mortality rates.

Risk factors for stroke in patients with HF and outcome {#s4b}
-------------------------------------------------------

Present facts concerning other risk factors for stroke in HF (apart from AF as the major factor) are primarily grounded on retrospective studies, cohort studies or post-hoc analyses of large clinical trials with significant inconsistencies.[@R34] This study reported age, diabetes mellitus, hypertension, hyperlipidaemia, peripheral vascular disease and AF to be independently associated with recurrent stroke risk in patients with HF. The Olmsted County cohort demonstrated that prior stroke, advanced age and diabetes were relevant stroke risk factors in 630 patients with HF,[@R12] whereas a history of AF or hypertension did not reach statistical significance according to multivariable analysis. On the other side, a retrospective analysis of the prospective Survival and Ventricular Enlargement (SAVE) study also reported no significant impact of hypertension (and diabetes) in 2231 patients with HF.[@R35] In contrast to these reports, the SCD-HeFT-study revealed an HR of 1.9 (95% CI 1.1 to 3.1) for stroke when hypertension was present at randomisation of 2144 patients with HF without AF.[@R9] In addition, a medical history of hypertension was associated with an increased risk of hospitalisation for stroke (HR 1.4; 95% CI 1.01 to 1.8) in 7788 patients with HF of the Digitalis Investigation Group trial.[@R36] Furthermore, our result is compatible from the age point of view with the Olmsted County data that revealed a significant but modest association between stroke risk and advanced age (relative risk 1.04; 95% CI 1.02 to 1.06).[@R12] An exploratory analysis of the SAVE study also showed similar results (relative risk of stroke 1.18; 95% CI 1.05 to 1.3, for each increase of 5 years in age),[@R9] while these results contradict the result of the Framingham Study that indicated that advanced age does not account for the increased risk of stroke in patients with HF[@R3] [@R37]

This study has shown that patients with HF with stroke had higher in-hospital mortality with longer hospital stay and that they are less likely to stay alive at 1-year follow-up, probably explained by the multiple comorbidities in this patient population. Many retrospective database analyses have shown that stroke increases the disability and mortality of patients with HF through the alteration in neuropsychological status, like decreased attention and concentration, memory loss, diminished psychomotor speed and decreased executive function, and this ranged from approximately 25--80% of all patients with chronic HF.[@R38]

Cardiologist vs internist care of patients with HF with prior stroke {#s4c}
--------------------------------------------------------------------

Cardiologists when compared with internists may provide more evidence-based therapies for the treatment of patients with HF.[@R42] [@R43] This is supported by this study, where patients under the care of cardiologists had a lower risk of recurrent in-hospital stroke, major bleeding, the need for blood transfusion and lower in-hospital and 1-year mortality rates when compared with patients managed by internists. This suggests that patients with prior stroke are a higher risk group which may benefit from specialised care. On the other hand, the observational nature of this study does not adjust for the possibility of selection bias in that patients with "lower" risk stroke were "preferentially" admitted under the care of cardiologists rather than internists.

Study limitations {#s5}
=================

This study is a subanalysis of an observational study, which is like any observational study, where the possibility for unmeasured confounding variables exists. In addition, not all hospitals in each country participated; hence, the results cannot be generalised. This study did not record the cognitive status and the disability status in patients with stroke, which obviously have a major impact on morbidity and mortality and only 1-year mortality. Mortality rates at follow-up were only recorded at 1 year without the specification of the exact date of death of each patient, and hence the Kaplan-Meier curves could not have been done. Finally, no information was available regarding the cause of stroke (embolic vs thrombotic). Future studies need to overcome these limitations.

Conclusion {#s6}
==========

This observational study reports a high prevalence of prior stroke in Middle Eastern patients with HF. There was underuse of anticoagulation therapy in patients with stroke and HF with AF. Patients with stroke hospitalised with HF were more likely to be admitted under the care of internists rather than cardiologists, resulting in less use of evidence-based medications and worse outcome. Patients with stroke had a higher risk of in-hospital recurrent strokes and higher long-term mortality rates. History of stroke was an independent predictor of in-hospital and 1-year mortality rates in patients hospitalised with HF. Future studies are needed to evaluate whether aggressive evidence based therapies to this high-risk group will improve outcome.

We thank Hani Altaradi and Kazi Nur Asfina for research coordination.

**Contributors:** KS, KFA, NA, AA-A, MA-J, BB, WA, MR, NB, HA, AA-M, HA, AE, PP and JA were involved in the design of the Gulf CARE registry and patient enrolment and ensuring quality control of the study. RS carried out the statistical analyses. All authors contributed to the drafting of the article and approved the final version of the manuscript.

**Funding:** Gulf CARE is an investigator-initiated study conducted under the auspices of the Gulf Heart Association and funded by Servier, Paris, France; and (for centres in Saudi Arabia) by the Saudi Heart Association.

**Competing interests:** None.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing statement:** No additional data are available.
